Tryngolza (olezarsen) approved for severe hypertriglyceridemia (Jun 24 2026)
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (1/13/26) through T+5. Run-up high $86.5 on 2/12/26, low $69.68 on 3/27/26 (T-120 to T-1). FDA decision 6/30/26. Historical price action, not a forecast.
Key facts
FDA decision date2026-06-30
OutcomeApproved
Drug / candidateOlezarsen - (CORE)
IndicationHypertriglyceridemia
CompanyIonis Pharmaceuticals
Market-cap tierLarge
120-day run-up (T-120→T-1)-1.0%
Cohort decision-day move (history)±1% median
Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier — history, not a prediction.